While other big pharmas have faltered, Lilly made headway in a Phase 3 trial that could provide a treatment option to replace fulvestrant.

Clinical Cancer Research publishes articles that focus on innovative clinical and translational research bridging the laboratory and the clinic. Topics include targeted therapies; mechanisms of drug ...

Incomplete applications will not be reviewed until all documentation is received. Learn from leaders in clinical immunology from the NHS across the UK and leading researchers from the Lydia Becker ...

These positive safety and efficacy indicators support the progression of the clinical trial and reinforce confidence in the therapeutic potential of ARO-CFB, thus underpinning the Buy rating.